Drugs / L2-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07010926 | Aug 2025 → Dec 2026 expected | Crohn disease | L2 Bio, LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L2-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07010926 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT07010926 ↗ |